This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Stroke, Volume 56, Issue Suppl_1 , Page AWP230-AWP230, February 1, 2025. Hemorrhagic strokes (HS) are increasingly significant causes of disability and mortality worldwide, making the use of blood biomarkers for their diagnosis and prognosis critical.
Stroke, Volume 56, Issue Suppl_1 , Page AWP227-AWP227, February 1, 2025. Introduction:Intracerebral hemorrhage (ICH) is commonly associated with poor neurologic outcomes. Early intervention has been shown to improve patient prognosis, highlighting the necessity of sensitive biomarkers. Specifically, functional parameters (i.e.,
Stroke, Volume 56, Issue Suppl_1 , Page AWP35-AWP35, February 1, 2025. Neutrophils are reported to be critical mediators of to poor outcome after subarachnoid hemorrhage (SAH). Finally, as neutrophil counts (and the ratio of neutrophils to lymphocytes) are reported to be a biomarker for DCI, we assessed these measures too.
Stroke, Volume 56, Issue Suppl_1 , Page ATMP1-ATMP1, February 1, 2025. A cerebral aneurysm (CA) is an abnormal artery deformation in the brain that may lead to hemorrhagic stroke, brain damage, coma, and even death when a CA ruptures. We hypothesized that increasing CA sample size will allow more robust biomarker identification.
Stroke, Volume 56, Issue Suppl_1 , Page ATP44-ATP44, February 1, 2025. It is closely linked to Alzheimer's disease (AD) and predisposes elderly patients to intracerebral hemorrhage and cognitive impairment. However, no effective serum biomarker has been established for early diagnosis or prediction of the disease progression.
Stroke, Volume 56, Issue Suppl_1 , Page AWP226-AWP226, February 1, 2025. Objective:Hematoma expansion (HE) predicts disability and death after intracerebral hemorrhage (ICH). Specific biomarkers of platelet activity would improve our understanding of HE and could point towards targeted treatments.
Stroke, Volume 56, Issue Suppl_1 , Page AWMP32-AWMP32, February 1, 2025. Our outcomes were differentially expressed protein (DEP) levels between patients with acute ischemic stroke (AIS), intracerebral hemorrhage (ICH), transient ischemic attack (TIA), and stroke mimics (MIM). For pairwise comparisons, we identified the DEPs using 1.5-fold
Stroke, Volume 56, Issue Suppl_1 , Page ATMP4-ATMP4, February 1, 2025. Introduction:Early brain injury (EBI), a complex collection of pathophysiological processes occurring within 72 hours aneurysmal subarachnoid hemorrhage (aSAH), is the key link connecting the initial event to the delayed and long-term complications.
Stroke, Volume 56, Issue Suppl_1 , Page ATP310-ATP310, February 1, 2025. Introduction:Intracerebral Hemorrhage (ICH) is associated with a high case fatality and survivors of ICH are at increased risk for ICH recurrence. Roughly 20-30% of patients with ICH take a statin at the time of ICH onset.
Stroke, Volume 56, Issue Suppl_1 , Page AWP370-AWP370, February 1, 2025. Approximately 30% of aneurysmal subarachnoid hemorrhage (aSAH) patients who survive the rupture develop delayed cerebral ischemia (DCI) 4 to 10 days following aSAH.
Stroke, Volume 56, Issue Suppl_1 , Page AWP224-AWP224, February 1, 2025. Background:The astroglial protein GFAP (glial fibrillary acidic protein) is a promising biomarker candidate for prehospital differentiation between intracerebral hemorrhage (ICH) and ischemic stroke.
Stroke, Volume 56, Issue Suppl_1 , Page AWP232-AWP232, February 1, 2025. Background:Intracerebral hemorrhage (ICH) is a critical neurological condition with high rates of mortality and morbidity. However, fully adopting this biomarker for mortality outcome prediction requires further analysis of heterogeneity sources.
Stroke, Volume 56, Issue Suppl_1 , Page ATP343-ATP343, February 1, 2025. Background:Subarachnoid Hemorrhage (SAH) accounts for 2-7% of strokes and has high mortality and morbidity. The identified genes and networks may guide the search for potential biomarkers of outcome and novel treatment targets.
Stroke, Volume 56, Issue Suppl_1 , Page AWMP79-AWMP79, February 1, 2025. Background and Purpose:The inflammatory response after ischemic and hemorrhagic stroke is associated with worse clinical outcomes through immune mediated production of pro- inflammatory cytokines. Of 25 enrolled patients, mean age was 65.8 (SD,
Stroke, Volume 56, Issue Suppl_1 , Page A47-A47, February 1, 2025. Introduction:The rapid identification of acute intracerebral hemorrhage (ICH) in patients with symptoms of acute stroke is decisive for prehospital triage and initiation of targeted therapies.
Stroke, Volume 56, Issue Suppl_1 , Page AWP338-AWP338, February 1, 2025. From those, intraplaque hemorrhage was the most common feature (81.1%).Proteomic Furthermore, these patients could benefit from early surgical intervention if these biomarkers were to be detected. of patients had symptomatic disease.
Stroke, Volume 56, Issue Suppl_1 , Page ATP209-ATP209, February 1, 2025. This workflow, which involves downloading imaging data from a clinical trials electronic data capture (EDC) system, performing biomarker analyses, and then re-entering data into the EDC, can be cumbersome when performed manually.
Stroke, Volume 56, Issue Suppl_1 , Page ATP320-ATP320, February 1, 2025. Further subgroup analysis revealed significant differences between ischemic stroke and hemorrhagic stroke subgroups (P=0.03).Conclusions:These The alterations in this pathway have been confirmed in psychiatric disorders, but their role in stroke remains unclear.
Stroke, Volume 56, Issue Suppl_1 , Page AWMP42-AWMP42, February 1, 2025. Males=147; Right Hemisphere=131; Ischemic=199, Hemorrhagic=27). The integrity of the corticospinal tract has frequently been suggested as a biomarker of stroke recovery. PREP-2), and been recommended for use in screening for clinical trials.
Stroke, Volume 56, Issue Suppl_1 , Page ATMP25-ATMP25, February 1, 2025. Introduction:Glial fibrillary acidic protein (GFAP), highly brain-specific, is emerging as an attractive blood biomarker in acute stroke.
Stroke, Volume 56, Issue Suppl_1 , Page AWMP99-AWMP99, February 1, 2025. Introduction:Circulating plasma protein profiling in individuals with brain vascular disorders may aid in the identification of robust diagnostic biomarkers, stratification of high-risk patients for treatment, and monitoring of disease progression or treatment response.
Stroke, Volume 56, Issue Suppl_1 , Page ADP47-ADP47, February 1, 2025. Introduction:Chronic kidney disease (CKD) is a risk factor for intracerebral hemorrhage (ICH) and for worse outcomes following ICH.
Stroke, Volume 56, Issue Suppl_1 , Page ATMP3-ATMP3, February 1, 2025. Cerebral aneurysms (CA) arise from the sites of weakened artery walls in the brain, and they may cause hemorrhagic stroke, coma, and death when they rupture. Studies have revealed sex differences in ~1.5 times higher prevalence of CA and ~1.5
Stroke, Volume 56, Issue Suppl_1 , Page AWP178-AWP178, February 1, 2025. Background and Objective:Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage and cognitive dysfunction in the elderly, and frequently coexists with Alzheimers disease (AD) and tau pathology.
Stroke, Volume 56, Issue Suppl_1 , Page AWMP14-AWMP14, February 1, 2025. Introduction:Cerebral microbleeds (CMBs) are age-related manifestations of microangiopathies predisposing patients to hemorrhagic stroke (HS) and cognitive decline. Little work has currently been done to elucidate mechanisms in the pathophysiology of CMBs.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content